FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1743-1749 June 7, 2001 Number 23 Next

	Full Text PDF Editorial by Utiger, R. D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Women with hypothyroidism that is being treated with thyroxine often need higher doses when they are pregnant. Whether this need can be attributed solely to estrogen-induced increases in serum thyroxine-binding globulin or whether other factors are involved is not known.

Methods In 11 postmenopausal women with normal thyroid function and 25 postmenopausal women with hypothyroidism treated with thyroxine, I assessed thyroid function before they started estrogen therapy and every 6 weeks for 48 weeks thereafter. The women with hypothyroidism included 18 women receiving thyroxine-replacement therapy and 7 women receiving thyrotropin-suppressive thyroxine therapy. On each occasion, serum thyroxine, free thyroxine, thyrotropin, and thyroxine-binding globulin were measured.

Results In the women with normal thyroid function, the serum free thyroxine and thyrotropin concentrations did not change, whereas at 12 weeks the mean (±SD) serum thyroxine concentration had increased from 8.0±0.9 µg per deciliter (103±12 nmol per liter) to 10.4±1.5 µg per deciliter (134±19 nmol per liter, P<0.001) and the serum thyroxine-binding globulin concentration had increased from 20.3±3.5 mg per liter to 31.3±3.2 mg per liter (P<0.001). The women with hypothyroidism had similar increases in serum thyroxine and thyroxine-binding globulin concentrations during estrogen therapy, but their serum free thyroxine concentration decreased from 1.7±0.4 ng per deciliter (22±5 pmol per liter) to 1.4±0.3 ng per deciliter (18±4 pmol per liter, P<0.001) and their serum thyrotropin concentration increased from 0.9±1.1 to 3.2±3.1 µU per milliliter (P<0.001). The serum thyrotropin concentrations increased to more than 7 µU per milliliter in 7 of the 18 women in the thyroxine-replacement group and to more than 1 µU per milliliter in 3 of the 7 women in the thyrotropin-suppression group.

Conclusions In women with hypothyroidism treated with thyroxine, estrogen therapy may increase the need for thyroxine.

Source Information

From the Division of Clinical and Molecular Endocrinology, Case Western Reserve University and the University Hospitals of Cleveland, Cleveland. Presented in part at the 81st Endocrine Society Meeting, San Diego, Calif., June 12–15, 1999.

Address reprint requests to Dr. Arafah at the Division of Clinical and Molecular Endocrinology, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106.

Full Text of this Article

This article has been cited by other articles:

• Bisschop, P. H, Toorians, A. W, Endert, E., Wiersinga, W. M, Gooren, L. J, Fliers, E. (2006). The effects of sex-steroid administration on the pituitary-thyroid axis in transsexuals.. Eur J Endocrinol 155: 11-16 [Abstract] [Full Text]  
• Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., Annibale, B. (2006). Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis.. NEJM 354: 1787-1795 [Abstract] [Full Text]  
• Huang, S. A., Mulcahey, M. A., Crescenzi, A., Chung, M., Kim, B. W., Barnes, C., Kuijt, W., Turano, H., Harney, J., Larsen, P. R. (2005). Transforming Growth Factor-{beta} Promotes Inactivation of Extracellular Thyroid Hormones via Transcriptional Stimulation of Type 3 Iodothyronine Deiodinase. Mol. Endocrinol. 19: 3126-3136 [Abstract] [Full Text]  
• Qatanani, M., Zhang, J., Moore, D. D. (2005). Role of the Constitutive Androstane Receptor in Xenobiotic-Induced Thyroid Hormone Metabolism. Endocrinology 146: 995-1002 [Abstract] [Full Text]  
• (2004). Body Mass Index and Insulin Resistance. Obstet Gynecol 104: 5S-10S [Full Text]  
• Hach, I., Rentsch, A., Ruhl, U. E, Becker, E. S, Turke, V., Margraf, J., Kirch, W. (2004). Drug Use Patterns in Young German Women and Association with Mental Disorders. The Annals of Pharmacotherapy 38: 1529-1534 [Abstract] [Full Text]  
• Alexander, E. K., Marqusee, E., Lawrence, J., Jarolim, P., Fischer, G. A., Larsen, P. R. (2004). Timing and Magnitude of Increases in Levothyroxine Requirements during Pregnancy in Women with Hypothyroidism. NEJM 351: 241-249 [Abstract] [Full Text]  
• Blazer, S., Moreh-Waterman, Y., Miller-Lotan, R., Tamir, A., Hochberg, Z.'e. (2003). Maternal Hypothyroidism May Affect Fetal Growth and Neonatal Thyroid Function. Obstet Gynecol 102: 232-241 [Abstract] [Full Text]  
• Streetman, D. D, Khanderia, U. (2003). Diagnosis and Treatment of Graves Disease. The Annals of Pharmacotherapy 37: 1100-1109 [Abstract] [Full Text]  
• Siraj, E. S., Gupta, M. K., Reddy, S. S. K. (2003). Raloxifene Causing Malabsorption of Levothyroxine. Arch Intern Med 163: 1367-1370 [Abstract] [Full Text]  
• Freund, K. M., Dolan, N. C., Nelson, H. D. (2003). Update in Women's Health. ANN INTERN MED 138: 119-127 [Full Text]  
• (2001). Hypothyroid Women Taking Estrogen May Need Increased Thyroxine Dosage. JWatch Women's Health 2001: 2-2 [Full Text]  
• (2001). Thyroxine Dosing for Women on Postmenopausal Estrogen Therapy. JWatch General 2001: 2-2 [Full Text]  
• Utiger, R. D. (2001). Estrogen, Thyroxine Binding in Serum, and Thyroxine Therapy. NEJM 344: 1784-1785 [Full Text]